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Abstract
Background: Many Brazilian patients with complex diseases who are treated in tertiary referral clinics have been
stable for long periods. The main needs of these patients involve monitoring of risk factors and review of drug
prescriptions, which could be satisfactorily done in primary care facilities. The goal of this protocol is to evaluate the
safety and effectiveness of telemedicine services to support the transition of patients with stable chronic coronary
artery disease from the tertiary to the primary level of care.
Methods/design: We designed a randomized non-inferiority protocol that will include 280 patients with stable
coronary artery disease (for at least 12 months). Patients will be selected from the Ischemic Heart Disease Clinic in a
tertiary care hospital in southern Brazil. Enrolled participants will be randomized into one of two groups: 12 months
of follow-up at the same clinic; or 12 months of follow-up at a primary care facility with clinical support from a
telemedicine platform including a toll-free line for physicians (intervention group). In the intervention group,
decisions to refer patients to tertiary care during follow-up will be made jointly by primary physicians and medical
teleconsultants. The groups will be compared in terms of the primary outcome—maintenance of baseline functional
class 1 or 2 after 12 months. Secondary outcomes include control of risk factors and instability of the disease.
Discussion: We intend to determine the effectiveness of using telemedicine to qualify the transition of patients with
chronic coronary disease from the tertiary to the primary level of care. This should facilitate the access of patients to
the healthcare system, since care will be provided closer to their homes, and provide more opportunities for treatment
of severe cases at tertiary care hospitals that are often overcrowded.
Trial registration: ClinicalTrials.gov # NCT02489565 – trial registration date May 13, 2015
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Background
Coronary artery disease (CAD) is characterized by a
wide range of clinical presentations. In many patients,
CAD remains stable for long periods, with fairly steady
symptoms over time, whereas in others the presence of
multiple cardiovascular events entails the need for revas-
cularization [1]. With a greater number of diagnoses and
increased survival following treatment of acute ischemic
CAD, the number of patients experiencing stable angina
has increased progressively worldwide. In Brazil, 18
thousand new cases of CAD and 900 thousand new
cases of angina pectoris are expected every year [2].
The Brazilian public health care system—the Unified
Health System (SUS)—was designed to provide univer-
sal, comprehensive healthcare to all Brazilian citizens.
However, complex technologies, financial resources, and
qualified personnel are currently concentrated in large
cities, with marked regional inequality [3]. In Porto
Alegre, state capital of Rio Grande do Sul, only about
50 % of CAD patients treated in a specialized outpatient
clinic at a tertiary care university hospital (Hospital de
Clinicas de Porto Alegre, HCPA) live in the city. The
other 50 % are referred from other cities in the state Rio
Grande do Sul. Some patients travel as much as 8 h to
reach the hospital. This situation also causes overcrowd-
ing of the tertiary clinic and restricts access, making it
difficult to book urgent appointments and prioritize the
most severe cases. The performance of specialized tests
and exams is often delayed.
Nevertheless, many of the patients seeking care in
Porto Alegre could be managed in their city of origin
within the context of primary care, defined as “that as-
pect of a health services system that assures (…) com-
prehensiveness of care in the sense that only rare or
unusual manifestations of ill health are referred else-
where, and coordination of care such that all facets of
care (wherever received) are integrated” [4]. SUS is
based on a logic of referral and counter-referral, accord-
ing to which less technologically dense services may
refer patients for care at greater complexity facilities,
namely, hospitals and specialized clinics; and these com-
plex services can refer the patient back for follow-up at
primary care facilities that are closer to the patient’s
home [5, 6]. Because of structural limitations, including
health care professionals who feel unprepared or unsup-
ported to treat situations they deem as complex, the re-
ferral and counter-referral system is often bypassed.
In this context, telemedicine provides a useful tool
for diagnostic and therapeutic support as well as con-
tinuing health education. Telehealth appointments in-
volving workers, health professionals, and managers
can be used to clarify doubts about clinical proce-
dures and health actions and answer questions re-
garding the work process [7].
This article describes a protocol designed to evaluate
the use of telemedicine to support the counter-referral
of stable CAD patients treated in a tertiary outpatient
clinic to primary care facilities, with remote assistance
for routine follow-up and decision-making regarding the
need for care at the tertiary clinic in the presence of
clinical instability. This initiative is intended to facilitate
the access to tertiary services for patients with more se-
vere conditions, reduce delays in booking appointments




This randomized non-inferiority trial was designed to
compare two groups: CAD patients meeting outpatient
clinic discharge criteria, counter-referred from tertiary
to primary care for follow-up with telemedicine moni-
toring (intervention group); and CAD patients meeting
outpatient clinic discharge criteria with follow-up at the
original tertiary care outpatient clinic (control group).
Study population and sample size
The study population will be selected among patients
from the Ischemic Heart Disease outpatient clinic at
HCPA, a tertiary care university hospital in South Brazil.
All clinic patients have CAD defined by the presence of
at least one of the following: documented history of
myocardial infarction, surgical or percutaneous myocar-
dial revascularization, lesion > 50 % in at least one cor-
onary artery assessed by angiography, or presence of
angina and positive noninvasive testing of ischemia [8].
Study participants will undergo standard anamnesis
and medical examination to verify clinical stability and
discharge criteria.
The sample size was calculated as 140 patients in each
group—considering a non-inferiority margin of 10 % and
incidence of 92 % of the main outcome, that is, mainten-
ance of Canadian Cardiovascular Society Functional
Classification (CCS) 12 months after the start of follow-
up. This was based on the rate of patients with increase
in angina to a higher CCS reported by a previous study
for the control group receiving optimal treatment for
CAD [9]. An additional 10 % margin was added to ac-
count for losses to follow-up. For calculation of sample
size, a ß of 0.9 and an α of 0.05 (two-sided) were
considered.
Inclusion and exclusion criteria
Individuals of both genders, aged ≥ 18 years, with a diag-
nosis of CAD and CCS I or II at the moment of enroll-
ment, without cardiovascular events requiring hospital
admission during the previous year, will be selected for
the study. Verification of discharge criteria will be
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performed by the medical team running the clinic, with-
out interference from the investigators.
Patients who have been followed-up at the clinic for
less than 1 year, unstable patients needing medication
adjustments, patients performing diagnostic evaluation
at the moment of enrollment, or those who do not agree
with the outcome of randomization will be excluded.
Interview and questionnaires
Eligible individuals will be invited at the outpatient
clinic, after their regular appointment, to participate in
the study. At study entry, patients will undergo a base-
line interview (Fig. 1). Interviews will be performed by a
trained professional using a standard pre-coded ques-
tionnaire. The following information will be collected by
interview or review of medical records: (i) clinical and
epidemiological data: previous diagnoses, including
chronic heart failure, peripheral arterial disease, acute
myocardial infarction (AMI), chronic arterial disease,
chronic obstructive pulmonary disease (COPD), dyslipid-
emia and diabetes; Canadian Cardiovascular Society
(CCS) Functional Classification of Angina grade at the
moment of the interview [10]. (ii) Biological factors: age
and sex. (iii) Socioeconomic factors: skin color, social
class, literacy, income, and schooling. (iv) Lifestyle: alco-
hol consumption, smoking, and practice of physical
activities. (v) Use of medications: dose and type of medi-
cations, adherence to drug treatment (measured by an
adapted version of the Brief Medication Questionnaire).
(vi) Laboratory tests and medical procedures performed.
Intervention
The intervention will be discharge from the tertiary out-
patient clinic and referral to the primary care facility
nearest to the home address, with clinical support from
an existing telemedicine platform and a toll-free hotline
(TelessaúdeRS/UFRGS). Prompt access to the tertiary
outpatient clinic will be ensured in acute situations fol-
lowing agreement between primary physicians and tele-
consultants. The toll free line is accessible to primary
care physicians is available Monday through Friday, from
8:00 a.m. to 5:30 p.m. [11].
A TelessaúdeRS/UFRGS team designated for the pro-
ject includes one specialized cardiologist with access to
the patient’s electronic record, whose role will be to aid
primary care physicians in patient management, and a
medical student dedicated to manage and monitor the
study flowchart.
The control group will undergo the routine follow-up
scheme, with appointments scheduled every six months
or once yearly at the outpatient Ischemic Cardiopathy
Clinic at HCPA.
Randomization
Patients eligible for inclusion will be randomized 1:1
using random block sizes of six and four, by a computer-
ized list provided by randomization.com. The investiga-
tor in charge of randomization will not be involved in
determination of eligibility or assessment of outcomes.
Group assignment will be performed by opening a sealed
opaque envelope in front of the patient after signature of
the informed consent form and completion of the initial
research questionnaire. After that, the groups will be
managed as follows (Fig. 1):
– Telehealth group (intervention group): the patient
will be discharged from the tertiary care outpatient
clinic and directed to a primary care facility (Basic
Health/Family Health Strategy unit) previously
identified according to residential address. At the
primary care facility, patients will book a routine
appointment within two months. For that, the
patient will bring the discharge note, comprising all
relevant information about the case, medical
prescriptions, and a counter-reference note with
therapeutic planning. The TelessaúdeRS/UFRGS
team will contact the basic health unit and provide
access to the telehealth platform for follow-up
monitoring. A teleadvisory will be scheduled
between the medical teleconsultants and the primary
Fig. 1 Flow Diagram of Study Design
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physicians within two months after outpatient clinic
discharge to discuss clinical management of the
patient. Furthermore, primary physicians can call
the support team at TelessaúdeRS/UFRGS whenever
they have doubts about the clinical management.
Patients will be interviewed by telephone at four and
eight months of follow-up using the standardized
instrument used at study entry. The calls will be
made by independent evaluators, hired and trained
specifically for this purpose. An appointment will be
booked at 12 months of follow-up for final evaluation
of the patient.
– Control group: patients will undergo the usual flow
routine during the study period. Patients will be
interviewed by telephone using the standardized
instrument at four and eight months of follow-up.
An appointment will be booked at 12 months of
follow-up for final evaluation of the patient. If
clinical status is stable, the patient will no longer
attend the tertiary outpatient clinic for follow-up.
For all patients (intervention and control groups), the
12-month appointment will focus on evaluation of
symptoms, episodes of disease decompensation, and ad-
herence to treatment. Patients who do not show up for
the 12-month appointment will be contacted by tele-
phone. If the patient is not found, the study team will
contact the primary care facility to determine the
patient’s clinical status.
Outcome measures and assessment procedures
Telephone interviews aim to identify changes in func-
tional class or clinical events taking place over the
follow-up period.
The final 12-month interview will evaluate the same
components assessed in the initial interview, in order to
determine improvement/worsening of clinical status. All
patients will undergo blood tests with serum lipids and
glucose evaluation.
The primary outcome is maintenance of CCS I or II at
12 months.
Secondary outcomes focus on risk factors. Control of
risk factors will analyze variations of at least 5 % in the
following pre and post-intervention measurements [12]:
– systemic blood pressure;
– controlled dyslipidemia: LDL < 100 mg/dL;
– glycated hemoglobin (in the presence of diabetes);
– abstinence from tobacco smoking;
– about 150 min/week of regular physical activity.
Additional secondary outcomes include health care ac-
cess variables, such as: medical appointment in primary
care facility taking place within not more than six
months after referral, with review of medications and
issue of prescriptions; and disease instability during the
12-month follow-up, defined as the need for seeking
emergence care due to cardiovascular disease: acute
chest pain; heart failure decompensation; acute arrhyth-
mias; stroke.
Given the objective nature of the outcomes, the safety
of the intervention, and the brief follow-up period, end-
point adjudication and data monitoring committees will
not be appointed. No interim analyses are proposed. At
the 4 and 8-month telephone interviews patients will be
asked about possible unintended effects of the trial, and
will receive guidance as required. After the trial, patients
will be readmitted to the outpatient clinic if continued
care at a primary care facility is not available.
Statistical analysis
Continuous variables without normal distribution will be
described as mean ± standard deviation or median and
inter-quartile range (IQR). Categorical variables will be
expressed as percentages. Comparisons between groups
will be performed by Student’s t-test for continuous vari-
ables with normal distribution and Wilcoxon’s test for
variables without normal distribution. Fisher’s exact test
will be used for categorical variables. Logistic regression
analysis will be used to establish the effect of the
counter-referral strategy on primary and secondary out-
comes at 12 months. Analysis of survival free of events
at 12 months will be performed using the Cox multivari-
ate regression and described in Kaplan-Meier survival
curves. Variables with P < 0.10 in the univariate analyses
will be included in the multivariate model. Primary out-
come analysis will be according to intention to treat
(ITT). Determination of sample size has taken into con-
sideration a 10 % loss to follow-up.
Data will be analyzed in SPSS 18.0 for Windows.
Statistical significance is set at P < 0.05.
Ethical precautions
The study will be carried out in accordance with the
guidelines for Good Clinical Practice, the Declaration of
Helsinki, the Medical Research Involving Human
Subjects Act (WMA) and other applicable guidelines,
regulations and acts. Ethical approval was obtained from
the Institutional Review Board at Hospital de Clinicas de
Porto Alegre (CAAE: 28064614.0.0000.5327). All partici-
pants will be extensively informed about the study, in-
cluding confidentiality aspects and the right to withdraw
from the study at any time, without providing an explan-
ation and with no effect on the quality of treatment.
Written information will be provided prior to inclusion
and patients will express their agreement to participate
by signing a written consent form. The name and tele-
phone number of a physician will be provided for
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patients with questions about the research before, dur-
ing, and after the start of the protocol.
Study sponsor and funding agencies have not partici-
pated in study design and will not be involved in collec-
tion, management, analysis, and interpretation of data;
writing of the report; and the decision to submit the re-
port for publication. Because this is a single-center
study, a steering committee was not appointed.
Results will be submitted for publication in a peer-
reviewed journal after the end of the trial, without re-
strictions. Authorship will be defined according to the
recommendations of the International Committee of
Medical Journal Editors.
Discussion
Tertiary care services in Brazil are overcrowded, with re-
duced capacity to accept new patients and schedule new
appointments. At the HCPA Ischemic Cardiopathy
Clinic, in the city of Porto Alegre, more than 50 % pa-
tients come from other cities, located as far as 8 h away.
These patients face stressful trips and risk of road acci-
dents, among others. Only two new patients are evalu-
ated at the clinic every week. The large patient volume
also compromises the ability to provide urgent appoint-
ments, prioritize more severe cases, and perform test
such as echocardiograms and myocardial scintigraphy.
However, many of the patients seen at the clinic have
been stable for long periods, requiring only monitoring
of risk factors and re-evaluation of prescribed medicines.
These activities can be satisfactorily performed at a Basic
Health Unit/Family Health Program, with prompt refer-
ral to the tertiary hospital only in the presence of
instability.
It is believed that the mechanisms facilitating patient
referral and counter-referral are fundamental to assure
the principle of comprehensiveness, suitability of care
for the patient, and rational use of resources [13]. Tele-
health centers can help improve the effectiveness of
counter-referral and management of stable chronic
cases, thus preventing the overcrowding of specialized
services and ensuring good quality follow-up near the
patient’s home [14]. A previous protocol carried out by
our telehealth program (TelessaúdeRS/UFRGS) showed
that referral to a higher level of care was avoided in one
out of every two cases following discussion with tele-
health specialists [15].
The main risk for participants of the present protocol
is violation of data confidentiality. All possible measures
will be taken by investigators to prevent this. A single
patient identification number will be used. Direct bene-
fits are not expected either. However, the information
obtained will serve to improve the management of pa-
tients with stable CAD. The results of this work will also
provide important information on the best way to allo-
cate technological resources in this area.
It is expected that the quality of follow-up and moni-
toring of ischemic cardiopathy will be similar in the ter-
tiary clinic and with the primary care/telemedicine
scheme. If that is confirmed, stable patients will in the
future have access to treatment close to their homes,
while opening space for more severe patients who have
no choice but to be treated in a tertiary hospital.
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